Corcept Therapeutics (CORT) Q3 2026 earnings summary

Executive summary

• Q3 2026 revenue was $340.5M, up 64% YoY; net income was $126.8M versus $19.7M in Q3 2025.

• FY2026 revenue guidance was reiterated at $1.1B–$1.2B, with growth expected in endocrinology and oncology.

Financial highlights

• Q3 revenue was $340.5M versus $207.6M; operating income was $114.7M versus $10.2M, and net income was $126.8M versus $19.7M.

• Nine-month revenue was $761.5M versus $559.3M; net income was $138.0M versus $75.4M.

• Cash, cash equivalents and marketable securities totaled $662.3M at September 30, 2026, up from $544.6M at June 30.

• Q3 diluted EPS was $1.01 versus $0.16; nine-month diluted EPS was $1.13 versus $0.62.

Outlook and guidance

• FY2026 revenue guidance remained $1.1B–$1.2B; R&D expense is expected to be approximately the same as in 2025, while SG&A is expected to be higher.

• Relacorilant’s Cushing’s syndrome NDA has a December 17, 2026 FDA target date; a European Commission decision on the ovarian cancer application is expected by year-end.

• BELLA Parts B and C, TRIDENT and SYNERGY data are expected in 2027; a Phase 3 ALS trial is planned to begin in 2027.

• Existing Cushing’s syndrome business is expected to generate at least $2B in annual revenue by decade-end; relacorilant could drive $3B–$5B in 2030, while Lifyorli has more than $1B in annual revenue potential.